Lehrkurs

Medical Retina

3rd ESASO Module 2019

Datum:

25.02.2019, 07:45 - 01.03.2019, 12:20

Veranstalter:

European School for Advanced Studies in Ophthalmology ESASO

Kurzbeschreibung:

This 3rd module of the ESASO training courses in 2019 will focus on medical retina. International speakers will share their knowledge. The training course will take place in Rome, Italy.

Fortbildungspunkte: 25

Hinweis:

An application will be made to EACCME® for CME accreditation of this event.

Fachärzte

Max. Teilnehmer: unbegrenzt
Gebühren ab: 2.300,00 EUR

Hinweis:
Accomodation included

Ärzte/-innen in Weiterbildung

Max. Teilnehmer: unbegrenzt
Gebühren ab: 2.300,00 EUR

Hinweis:
Accomodation included.

Bemerkungen:

Diese Veranstaltung findet jährlich statt und bietet Fortbildungsmöglichkeiten für Fachärzte und Ärzte/-innen in Weiterbildung.

Die Zertifizierung wurde von der European Accreditation Council for Continuing Medical Education (EACCME) genehmigt.

Veranstaltungsnummer: 25970

Zertifizierung: genehmigt

CME Max.: 25

Gebühren ab:

ab 2.300,00

verfügbare Plätze: unbegrenzt

Sprache: Englisch

Vom Veranstalter gemeldetes Programm:

	MONDAY, 25 FEBRUARY 2019

07:45	Registration and welcoming

	NEW DIAGNOSTIC AND TREATMENT FOR DR

08:30	Stadiation of DR on Wide-Field imaging
09:00	Modification of the signs of DR on Wide-Field imaging following intravitreal treatment
09:30	OCT-A for Diabetic Retinopathy
10:00	Controversial point: the fluorescein angiography is still necessary for the diagnosis and stadiation of DR
10:30	COFFEE BREAK
11:00	Controversial point: No more fluorescein angiography for the diagnosis and stadiation of DR
11:30	New paradigms of treatment of PDR
12:00	Cases Study: PDR treatment
12:30	LUNCH

	DECISION MAKING IN THE TREATMENT OF DME

13:30	The identification of inflammatory biomarkers and their prognostic value
14:00	Differentiate DME vs AMD
14:30	Patients management with focus on inflammation and number of injections
15:00	Real life data on DME intravitreal treatments
15:30	COFFEE BREAK
16:20	Controversial point: Monthly intravitreal injections of anti-VEGF remain the first choice treatment of DME
16:40	Controversial point: A long-standing disease, as DME, needs a long lasting treatment
17:00	DME treatment: case study

	TUESDAY, 26 FEBRUARY 2019

08:30	Discerning the severity of dry AMD
12:30	LUNCH

	OCULAR COMPLICATIONS OF IV TREATMENT: RARE BUT REAL

13:30	Rhegmatogenous retinal detachment following intravitreal treatment: risk factors and outcomes
14:00	Endophthalmitis and sterile endophthalmitis following intravitreal treatment: diagnosis and treatment
15:00	COFFEE BREAK
15:30	Cataract, Glaucoma and other complications
16:00	Geographic atrophy secondary to intravitreal anti-VEGF treatment

	WEDNESDAY, 27 FEBRUARY 2019

	AMD

08:30	Discerning the severity of dry AMD
09:00	Diagnosis and natural progression of geographic atrophy, actual and future management
09:45	Nanoseconds and other lasers in Dry-AMD, mechanism of action, techniques, results
10:30	COFFEE BREAK
11:00	OCT-A features of Wet-AMD at baseline
11:45	Cases Study of Wet AMD management
12:30	LUNCH
13:30	Incoming new treatments for Wet-AMD
14:00	Cases Study of PCV management
14:45	COFFEE BREAK
15:15	Identification and classification of fibrosis in AMD
15:45	Cases study of exit strategy in the treatment of Wet-AMD

	THURSDAY, 28 FEBRUARY 2019

	MIOPIC MACULAR DEGENERATION CLINICAL PRACTICE COURSE

08:30	Morphology of the myopic macula and detection of its components
09:00	Features of myopic macular CNV at baseline and of the characteristics associated with good or bad visual acuity outcomes
09:45	Cases Study of Myopic CNV management
10:30	COFFEE BREAK
11:00	Long-term outcomes of myopic CNV intravitreal treatment
11:30	Controversial point: the intravitreal treatment of MMD must be guided first by morphological aspects
12:00	Controversial point: the intravitreal treatment of MMD must be guided first by visual acuity changes
12:30	LUNCH

	RVO CLINICAL PRACTICE COURSE

13:30	Features of RVO at baseline and of the characteristics associated with good or bad visual acuity outcomes
14:30	Protocols of treatment and long-term outcomes
15:00	COFFEE BREAK
15:30	Cases Study of RVO management
16:00	The role of inflammation in RVO
16:30	The utility of systemic and other therapies in RVO

	FRIDAY, 1st MARCH 2019

	OCT-A ESSENTIAL

08:30	OCT Angiography to differentiate intraretinal microvascular abnormalities (IRMA) from retinal neovascularization (RNV)
08:50	OCT angiography to differentiate collateral vessels in ischemic retinal vein occulsion
09:10	OCT Angiography to detect non-exudative choroidal neovascularization and vascularized drusen
09:30	OCT angiography to detect and monitor Quiescent Exudative AMD with persistent subretinal fluid
09:50	OCT Angiography to detect macular microvascular changes in patients with no evidence of diabetic retinopathy
10:10	COFFEE BREAK
10:40	OCT Angiography to detect AMD mimicking CSC and reverse
11:00	OCT Angiography to detect and differentiate a Mac-Tel from other intraretinal microvascular abnormalities
11:20	OCT Angiography to detect and differentiate ischemic optic neuritis from papilledema
11:40	OCT Angiography to detect and differentiate optic disc collateral vessel from neovascularization of the optic disc
12:00	OCT Angiography to detect haller and sattler layers alterations
12:20	Final Test and Farewell

Veranstaltungsort:

tba

Anschrift:

Rome, Italien

Veranstalter:

European School for Advanced Studies in Ophthalmology ESASO

Organisation:

European School for Advanced Studies in Ophthalmology ESASO
c/o Università della Svizzera italiana (USI)
Via G. Buffi 13
CH - 6904 Lugano
Tel.: +41 (0)58 666 46 29
Fax: +41 (0)58 666 46 19

Hinweis:

Registration required. Please contact the organizer for further information.